NCT00941395 is a NA clinical trial of Survey Administration in Cigarette Smoker, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT00941395?

NCT00941395 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00941395?

Interventions in NCT00941395: Survey Administration.

What condition does NCT00941395 study?

NCT00941395 studies Cigarette Smoker, Current Every Day Smoker.

Is NCT00941395 still recruiting?

NCT00941395 is currently completed. Last updated 21 November 2018.

Last reviewed 2018-11-21 · How we verify

NCT00941395

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enhanced Smoking Cessation for University Students

Completed NA Last updated 21 November 2018

What this trial tests

NA trial testing Survey Administration in Cigarette Smoker in 39 participants. Completed in 8 June 2017.

Timeline

30 June 2009

Primary endpoint
8 June 2017

8 June 2017

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	39
Start date	30 June 2009
Primary completion	8 June 2017
Estimated completion	8 June 2017
Sites	2 locations across United States

Drugs / interventions tested

Survey Administration

Conditions studied

Cigarette Smoker — all drugs for Cigarette Smoker →
Current Every Day Smoker — all drugs for Current Every Day Smoker →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 18 to 35, any sex, with Cigarette Smoker or Current Every Day Smoker. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies how well a new smoking cessation and prevention intervention works in enhancing smoking cessation for university students. The new intervention may be easier to use for students to quit smoke.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Survey Administration

Trials testing the same drug.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07377006 — Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer · NA · not yet recruiting
NCT07390968 — Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Pati · Phase 2 · not yet recruiting
NCT07493252 — A Behavioral Application for Improving Smoking Cessation Among Smokers · NA · not yet recruiting

Other recruiting trials for Cigarette Smoker

Currently open trials in the same condition.

NCT03865472 — rTMS in Promoting Smoking Cessation and Preventing Relapse in Current Smokers · NA · active not recruiting
NCT03199651 — Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer · NA · recruiting
NCT02697227 — Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation · NA · active not recruiting
NCT02271919 — Varenicline and Combined NRT for Smoking Cessation · Phase 4 · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00941395 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 21 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00941395.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing